Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference

NACompletedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

November 30, 2021

Study Completion Date

November 30, 2021

Conditions
Chronic Liver Disease
Interventions
DEVICE

FibroScan 530 Compact

The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.

Trial Locations (5)

35033

CHU Rennes Hôpital Pontchaillou - Service des Maladies du Foie, Rennes

75012

Hôpital Saint-Antoine - Service Hépatologie, Paris

93140

Hôpitaux Universitaires Paris Seine Saint-Denis - Service Hépatologie, Bondy

Unknown

Centre Hospitalier Universitaire d'Angers, Angers

Centre Hospitalier Universitaire de Bordeaux - Hôpital Haut Lévêque, Bordeaux

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Echosens

INDUSTRY